Meloxicam Zentiva (Meloxicam)

Meloxicam works by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the synthesis of prostaglandins—key mediators of inflammation, pain and fever—while largely preserving COX‑1 activity that protects the stomach lining.

The dose of Meloxicam Zentiva is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, renal and hepatic function, and other individual factors. No fixed regimen is provided here.

Safety data for meloxicam during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Meloxicam offers greater COX‑2 selectivity than non‑selective NSAIDs such as ibuprofen or naproxen, which can translate into a lower incidence of gastrointestinal irritation. However, it shares similar cardiovascular and renal risk profiles with other NSAIDs, so patient‑specific factors must guide selection.

Meloxicam Zentiva should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging. Do not freeze the product, and avoid shaking the vial before use to maintain solution integrity.

The product is supplied as an injectable solution for intramuscular injection. It should be administered by a qualified healthcare professional using aseptic technique, typically into a large muscle such as the gluteus maximus, following the recommended volume and injection site guidelines.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as myocardial infarction or stroke, and renal impairment that may lead to acute kidney injury. Patients should be monitored for signs of these complications, especially if they have pre‑existing risk factors.

Meloxicam should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, active peptic ulcer disease, severe heart failure, uncontrolled hypertension, significant renal or hepatic impairment, and in patients receiving certain anticoagulants where bleeding risk is unacceptable.